Skip to Main Content

Author Details

David D L Bowtell
Peter MacCallum Cancer Centre
1983
265
86
PMIDPaper TitleJournal TitlePublished Year
36287571A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.J Pathol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36366810Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.J Gynecol Oncol2023
36287571A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.J Pathol2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
38028140The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.Ther Adv Med Oncol2023
37858159UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.J Exp Clin Cancer Res2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36999648BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.Histopathology2023
36805919Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.Transl Oncol2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36730890<i>CCNE1</i> Amplification as a Therapeutic Target.J Clin Oncol2023
37225894Six-year experience of Australia's first dedicated cancer of unknown primary clinic.Br J Cancer2023
36849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023
37220750Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.Cell Rep Med2023
36720497Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.J Immunother Cancer2023
38028140The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.Ther Adv Med Oncol2023
37858159UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.J Exp Clin Cancer Res2023
37220750Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.Cell Rep Med2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36999648BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.Histopathology2023
37225894Six-year experience of Australia's first dedicated cancer of unknown primary clinic.Br J Cancer2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36720497Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.J Immunother Cancer2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
36849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023
36805919Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.Transl Oncol2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36730890<i>CCNE1</i> Amplification as a Therapeutic Target.J Clin Oncol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36366810Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.J Gynecol Oncol2023
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
35765251Psychological distress, understanding of cancer and illness uncertainty in patients with Cancer of Unknown Primary.Psychooncology2022
36095166The Tumor Microenvironment of Clear-Cell Ovarian Cancer.Cancer Immunol Res2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
35804177Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study.Support Care Cancer2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
35263119TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.J Clin Oncol2022
35804177Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study.Support Care Cancer2022
35765251Psychological distress, understanding of cancer and illness uncertainty in patients with Cancer of Unknown Primary.Psychooncology2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36095166The Tumor Microenvironment of Clear-Cell Ovarian Cancer.Cancer Immunol Res2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
35263119TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.J Clin Oncol2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
33806030Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.Cancers (Basel)2021
  • 1 - 50 of 530

Recommended Authors

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 2
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 20
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 2
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 9
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 2
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 81
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 4
Dongquan Chen
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 16
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 23
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 26
Agnes Viale
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 20
David Cogdell
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 3
Yi-Mi Wu
University of Michigan Medical School ann arbor
Career Start Year 1995
Number of shared co-authors 2
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 16
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 2
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 15
Denise C Connolly
Fox Chase Cancer Center
Career Start Year 1993
Number of shared co-authors 12
Wenbin Wei
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield
Career Start Year 1991
Number of shared co-authors 0
Rosemarie Schmandt
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 7
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 32
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 4
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 20
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 22
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 11
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 95
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 12
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 40
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 58

Collaborators

Anna DeFazio
Westmead Hospital
Co-authored papers 61
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 46
Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
Co-authored papers 37
Joshy George
Peter MacCallum Cancer Centre
Co-authored papers 35
Kathryn Alsop
Peter MacCallum Cancer Centre
Co-authored papers 33
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 31
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 30
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 26
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 26
David G Huntsman
University of British Columbia
Co-authored papers 26
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 25
Michael S Anglesio
University of British Columbia
Co-authored papers 24
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 24
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 23
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 23
Martin K??bel
University of Calgary
Co-authored papers 22
Ian G Campbell
Co-authored papers 19
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 18
Cyril B Gilks
University of British Columbia
Co-authored papers 17
Kylie L Gorringe
Co-authored papers 17
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 17
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 17
Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 16
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 16
Jennifer Alsop
University of Cambridge
Co-authored papers 16
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 16
Joy Hendley
Peter MacCallum Cancer Centre
Co-authored papers 15
Raghwa Sharma
Westmead Hospital
Co-authored papers 14
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 13
Stacey J Winham
Mayo Clinic
Co-authored papers 13
Release 1.2